RESONANCE HEALTH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.081 AUD | -4.71% |
|
+1.25% | +35.00% |
| Sales 2022 | 3.85M 2.47M | Sales 2023 | 4.47M 2.87M | Capitalization | 19.37M 12.43M |
|---|---|---|---|---|---|
| Net income 2022 | -1M -642K | Net income 2023 | - 0 | EV / Sales 2022 | 5.01 x |
| Net cash position 2022 | 6.51M 4.18M | Net cash position 2023 | 6.09M 3.91M | EV / Sales 2023 | 2.97 x |
| P/E ratio 2022 |
-22.4
x | P/E ratio 2023 |
-24.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.37% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.71% | ||
| 1 week | +1.25% | ||
| Current month | +15.71% | ||
| 1 month | +15.71% | ||
| 3 months | +58.82% | ||
| 6 months | +39.66% | ||
| Current year | +35.00% |
1 week
0.08
0.09
1 month
0.060.09
Current year
0.050.09
1 year
0.040.09
3 years
0.040.21
5 years
0.040.33
10 years
0.010.33
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Harrison
CEO | Chief Executive Officer | - | 23-06-30 |
John Olynyk
CTO | Chief Tech/Sci/R&D Officer | - | 21-11-23 |
Mitchell Wells
BRD | Director/Board Member | 48 | 17-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mitchell Wells
BRD | Director/Board Member | 48 | 17-03-31 |
Martin Blake
CHM | Chairman | - | 07-10-03 |
Simon Panton
BRD | Director/Board Member | - | 09-10-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.081 | -4.71% | 26,869 |
| 24-04-18 | 0.085 | +1.19% | 238,766 |
| 24-04-17 | 0.084 | +12.00% | 312,939 |
| 24-04-16 | 0.075 | 0.00% | 109,922 |
| 24-04-15 | 0.075 | -6.25% | 6,250 |
Delayed Quote Australian S.E., April 19, 2024 at 01:47 am EDT
More quotes
Resonance Health Limited is an Australia-based MedTech company. The Company specializes in the development and delivery of non-invasive medical imaging software and services. The Company is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.
Calendar
2024-08-26
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +35.00% | 23.25M | |
| +2.64% | 208B | |
| +1.80% | 174B | |
| +8.59% | 130B | |
| +16.47% | 98.97B | |
| -3.42% | 60.46B | |
| +12.71% | 51.73B | |
| -6.61% | 45.33B | |
| -4.53% | 38.9B | |
| +9.27% | 38.56B |
- Stock Market
- Equities
- RHT Stock
